nimodipine has been researched along with Dyskinesia, Drug-Induced in 3 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Isradipine-treated animals displayed a dose-dependent reduction in L-DOPA-induced rotational behavior and abnormal involuntary movements." | 1.35 | Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. ( Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ, 2009) |
| " Chronic administration of haloperidol (1 mg/kg, i." | 1.34 | Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schuster, S | 1 |
| Doudnikoff, E | 1 |
| Rylander, D | 1 |
| Berthet, A | 1 |
| Aubert, I | 1 |
| Ittrich, C | 1 |
| Bloch, B | 1 |
| Cenci, MA | 1 |
| Surmeier, DJ | 1 |
| Hengerer, B | 1 |
| Bezard, E | 1 |
| Bishnoi, M | 1 |
| Chopra, K | 1 |
| Kulkarni, SK | 1 |
| Soares, KV | 1 |
| McGrath, JJ | 1 |
1 review available for nimodipine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia.
Topics: Antipsychotic Agents; Calcium Channel Blockers; Diltiazem; Dyskinesia, Drug-Induced; Humans; Nifedip | 2000 |
2 other studies available for nimodipine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Mod | 2009 |
Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Topics: Animals; Behavior, Animal; Brain; Catalase; Dipyridamole; Dopamine; Dose-Response Relationship, Drug | 2007 |